Inclusion Criteria:
* Subject has presence of grade 2 (moderate) or grade 3 (severe) wrinkles according to SASSQ. The Investigator evaluates the wrinkles on both sides of the face as grade 2 or 3 SASSQ;
* Subject has mild to moderate photoaging according to Alexiades-Armenakas scale;
* Subject is willing and able to provide informed consent and attend follow-up visits;
* Subject is psychologically able to understand the study related information and to give a written informed consent (ICF);
* Subject has voluntarily provided written informed consent to participate in the study, and use of data privacy (sign the EC approved ICF), prior to any study-related procedure being performed;
* Subject is aged \>18 years;
* Subject is seeking correction of his/her facial wrinkles, agrees with recommendation by the Investigator, and has a reasonable expectation of the treatment effect;
* Subject accepts the obligation not to receive any other facial procedures or treatments impacting facial wrinkles at any time during the study (before their study exit);
* Subject is able to follow study instructions and likely to complete all required visits, as assessed by the Investigator, agree to maintain existing skincare habits during the trial period;
* Female of childbearing potential (who are sexually active, who do not have primary ovarian insufficiency, have not undergone hysterectomy or bilateral tubal ligation, who are not postmenopausal for at least 1 year) must have a negative urine pregnancy test (UPT) at screening (or prior to treatment on Visit 1) and Visit 3 (in case of touch-up treatment) and use a medically accepted contraceptive regimen (self-reported) since at least 12 weeks before the beginning of the study and during the study.
Exclusion Criteria:
In terms of population:
* Subject is a pregnant or breastfeeding woman, or planning a pregnancy during the study;
* Subject has scars, moles, tattoo, or anything on the face which might interfere with the evaluation;
* Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship;
* Subject in a social or sanitary establishment;
* Subject participating to another research on human beings or who is in an exclusion period of one month from a previous study;
* Subject needs to long-term outdoor work or long-term exposure to sunlight after treatment;
* Subjects who intend to initiate or continue any intentional weight-loss program (including diet, medication, or increased physical activity) during the study period;
* Subject has an adequate understanding of skin care after the treatment sessions: avoiding sun exposure, extreme temperature (sauna, hammam, etc.) or any source of UV rays 24 hours after the product application.
In terms of associated pathology:
* Subject presenting any symptom which can be related to a medical condition that is likely to make the subject not being compliant with the study schedule, at the discretion of the Investigator;
* Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results;
* Subject with known history of or suffering from autoimmune disease and/or immune deficiency, active connective tissue disorder (e.g., arthritis rheumatoid, scleroderma, and systemic lupus erythematosus), cancer, or receiving immunomodulatory agents;
* Subject suffering from active inflammatory and/or infectious cutaneous disorders in or near the studied zones (e.g. herpes, acne). Subject with recurrent herpes in the wrinkle area is not eligible even if asymptomatic at time of inclusion;
* Subject with a history of streptococcal disease, such as acute rheumatic fever or recurrent sore throats with cardiac localization;
* Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders;
* Subject having history of allergy or anaphylactic shock including hypersensitivity to hyaluronic acid or any of the other device components of the product or local anesthetic cream;
* Subject with a tendency to develop keloids or hypertrophic scars, or clinically significant skin pigmentation alterations.
Relating to previous or ongoing treatment:
* Subject participated in another clinical study in the last 30 days;
* Subject having received facial treatment with a laser, a dermabrasion, a surgery, a peeling, or other ablative procedure within the past 6 months prior to inclusion;
* Subject having received injection with a resorbable filling product in the face within the past 24 months prior to inclusion;
* Subject having received at any time injection with a slowly resorbable filling product (e.g. polylactic acid, calcium hydroxyapatite, combinations of HA and Hypromellose) or with a non-resorbable filling product (e.g. polyacrylamide or silicone);
* Subject having received at any time a treatment with tensor threads in the face;
* Subject currently undergoing or planning to undergo dental procedures that affect facial observation during the study (e.g., orthodontics, tooth extraction, dental implantation, etc.);
* Subjects having received surgical rhinoplasty procedure at any time;
* Subject under medications which may cause lipo-atrophy (e.g. Ozempic);
* Subject using medication such as aspirin, NSAIDs (e.g. ibuprofen), antiplatelet agents, anticoagulants, vitamin C within one week prior to inclusion or being a chronic user of anticoagulant treatment;
* Subject undergoing a topical treatment on the test area or a systemic treatment:
* Antibiotics and antihistamines during the 2 weeks prior to study start;
* Immunosuppressors and/or corticoids during the 3 months prior to study start;
* Retinoids during the 6 months prior to study start.
